[Application of low-molecular-weight heparin during pregnancy and delivery in case of reproductive failure due to antiphospholipid syndrome].
The authors report the results of application of low molecular weight heparin during pregnancy, delivery and after birth to counter placental insufficiency in case of primary antiphospholipid syndrome. The patient had been treated with Fraxiparin for 126 days. No systemic or local side effects were spotted. There were no genital bleeding and tromboembolic accidents during pregnancy. A Caesaerean section was carried out under spinal anaesthesia. Fraxiparin treatment was not halted during the section, which was accompanied by a normal blood loss. The pregnancy yielded an eutrophic newborn and no complications were demonstrated during the neonatal period.
Karag'ozova
Zh
Zh
Chernev
T
T
Iankova
Z
Z
Baleva
M
M
Dimitrov
A
A
D000328:Adult; D016736:Antiphospholipid Syndrome / Q000188:drug therapy; D001777:Blood Coagulation / Q000187:drug effects; D002585:Cesarean Section; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D017762:Nadroparin / Q000627:therapeutic use*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy* / Q000517:prevention & control; D011256:Pregnancy Outcome; D011292:Premedication; D013997:Time Factors
D006495:Heparin, Low-Molecular-Weight; D017762:Nadroparin